Compare HLIO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLIO | MNKD |
|---|---|---|
| Founded | 1970 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1996 | 2004 |
| Metric | HLIO | MNKD |
|---|---|---|
| Price | $64.16 | $2.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $65.50 | $8.64 |
| AVG Volume (30 Days) | 344.3K | ★ 6.6M |
| Earning Date | 03-02-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | ★ 23.93 | N/A |
| EPS | ★ 1.45 | 0.02 |
| Revenue | $200,727,000.00 | ★ $348,966,000.00 |
| Revenue This Year | $3.83 | $35.81 |
| Revenue Next Year | $4.84 | $11.89 |
| P/E Ratio | ★ $45.32 | $114.75 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $24.76 | $2.24 |
| 52 Week High | $76.47 | $6.51 |
| Indicator | HLIO | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 19.33 |
| Support Level | $62.73 | N/A |
| Resistance Level | $68.56 | $6.18 |
| Average True Range (ATR) | 2.54 | 0.13 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 27.63 | 10.85 |
Helios Technologies Inc is an industrial technology company that develops, manufactures, and markets solutions for the hydraulics and electronics markets. It operates under two business segments: Hydraulics and Electronics. The Hydraulics segment designs and manufactures hydraulic components and systems used to transmit power and control force, speed, and motion. There are two categories based on Hydraulic system architecture: MCT and FCT. The Electronics segment provides complete, fully-tailored display and control solutions for engines, engine-driven equipment, specialty vehicles, therapy baths, and traditional and swim spas. The company generates the majority of its revenue from the Hydraulics segment. Geographically, the company generates key revenue from the Americas region.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.